Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Corticosteroid use poses risk of febrile neutropenia

Chao CR et al. J Natl Compr Canc Netw. 2018;16(10):1201-8

Key clinical point: Risk factors for chemotherapy-induced febrile neutropenia include corticosteroid use and intravenous antibiotics.

Major finding: Corticosteroid use was associated with an increased risk of febrile neutropenia, compared with no corticosteroid use (hazard ratio, 1.53; P less than .01).

Study details: This retrospective study included 15,971 patients with non-Hodgkin lymphoma or five solid tumors.

Disclosures: The study was funded by Amgen. Three of the authors reported being employers and stockholders of Amgen.

Read the article.

Citation:

Chao CR et al. J Natl Compr Canc Netw. 2018;16(10):1201-8

This Week's Must Reads

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.

Haploidentical allo-HCT possible even in relapsed myeloma, Sahebi F, et al. Biol Blood Marrow Transplant. 2018 Sep 20. pii: S1083-8791(18)30575-5.

Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.

The role of PTPN22 R620W in CLL, Leukemia & Lymphoma 2018

Must Reads in Aggressive Lymphomas

Corticosteroid use poses risk of febrile neutropenia, Chao CR et al. J Natl Compr Canc Netw. 2018;16(10):1201-8

5F9 plus rituximab looks durable in NH, Advani R et al. N Engl J Med. 2018;379:1711-21

Age is an independent predictor of mortality after transplant, Kyriakou C et al. Biol Blood Marrow Transplant. 2018 Sep 13. doi: 10.1016/j.bbmt.2018.08.025

Complications in EPOCH-R versus R-CHOP, David RJ et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 29. doi: 10.1016/j.clml.2018.08.014

Cardiac assessment before doxorubicin treatment , Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85